Checkpoint Therapeutics Inc (CKPT)
1.85
-0.14
(-7.04%)
USD |
NASDAQ |
May 22, 16:00
1.85
0.00 (0.00%)
After-Hours: 20:00
Checkpoint Therapeutics Research and Development Expense (Quarterly): 8.497M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 8.497M |
| December 31, 2023 | 8.299M |
| September 30, 2023 | 5.496M |
| June 30, 2023 | 13.94M |
| March 31, 2023 | 15.83M |
| December 31, 2022 | 14.24M |
| September 30, 2022 | 8.866M |
| June 30, 2022 | 12.05M |
| March 31, 2022 | 14.67M |
| December 31, 2021 | 27.66M |
| September 30, 2021 | 9.384M |
| June 30, 2021 | 7.198M |
| March 31, 2021 | 4.213M |
| December 31, 2020 | 8.145M |
| September 30, 2020 | 2.543M |
| June 30, 2020 | 3.029M |
| March 31, 2020 | 2.635M |
| December 31, 2019 | 6.73M |
| Date | Value |
|---|---|
| September 30, 2019 | 3.894M |
| June 30, 2019 | 4.12M |
| March 31, 2019 | 4.581M |
| December 31, 2018 | 13.42M |
| September 30, 2018 | 7.848M |
| June 30, 2018 | 5.453M |
| March 31, 2018 | 6.932M |
| December 31, 2017 | 4.916M |
| September 30, 2017 | 4.955M |
| June 30, 2017 | 5.506M |
| March 31, 2017 | 3.704M |
| December 31, 2016 | 7.743M |
| September 30, 2016 | 4.713M |
| June 30, 2016 | 5.446M |
| March 31, 2016 | 2.365M |
| December 31, 2015 | 5.359M |
| September 30, 2015 | 3.485M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
2.543M
Minimum
Sep 2020
27.66M
Maximum
Dec 2021
9.072M
Average
8.222M
Median
Research and Development Expense (Quarterly) Benchmarks
| QuidelOrtho Corp | 59.20M |
| Fortress Biotech Inc | 24.84M |
| Anavex Life Sciences Corp | 9.257M |
| Ocugen Inc | 6.826M |
| NovaBay Pharmaceuticals Inc | 0.019M |